Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: Ripretinib
Trade Name:
Date Designated: 10/02/2014
Orphan Designation: Treatment of gastrointestinal stromal tumors (GIST)
Orphan Designation Status: Designated/Approved
Deciphera Pharmaceuticals, LLC
200 Smith Street
Waltham, Massachusetts 02451
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: Ripretinib
Trade Name:
Marketing Approval Date: 05/15/2020
Approved Labeled Indication: QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Exclusivity End Date: 05/15/2027 
Exclusivity Protected Indication* :  Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-